Alto Neuroscience, Inc. ANRO
We are a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Through insights derived from our scalable and proprietary Precision Psychiatry Platform, or our Platform, we aim to discover brain-based biomarkers to better identify which patients are more likely to respond to our novel product candidates. Our current pipeline consists of seven clinical-stage assets addressing high-need therapeutic areas, including major depressive disorder, or MDD, bipolar depression, or BPD, treatment resistant depression, or TRD, schizophrenia, and Parkinson's disease. Each of our programs, including our most advanced program — ALTO-207, are supported by robust clinical data in the respective patient populations in which we are developing them.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D | $45.6M | $47.0M | $30.3M | — |
| SG&A | $20.7M | $21.6M | $7.5M | — |
| Total operating expenses | $66.4M | $68.6M | $37.8M | — |
| Operating income | -$66.4M | -$68.6M | -$37.8M | — |
| Interest expense | $2.5M | $1.4M | $1.4M | — |
| Pre-tax income | -$63.2M | -$61.4M | -$36.3M | — |
| Income tax | $0 | $0 | $0 | — |
| Net income | -$63.2M | -$61.4M | -$36.3M | — |
| EPS, basic | -2.19 | -2.50 | -9.73 | — |
| EPS, diluted | -2.19 | -2.50 | -9.73 | — |
| Shares, diluted (wtd. avg.) | 28.9M | 24.6M | 3.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $176.5M | $168.2M | $82.5M | $48.3M |
| Total current assets | $177.7M | $169.3M | $85.4M | — |
| Property, plant and equipment | $1.9M | $2.7M | $1.1M | — |
| Total assets | $184.7M | $177.5M | $86.6M | — |
| Accounts payable | $1.9M | $1.6M | $1.1M | — |
| Short-term debt | $585.0K | $0 | — | — |
| Total current liabilities | $11.3M | $10.0M | $5.6M | — |
| Long-term debt | $16.2M | $10.3M | $9.9M | — |
| Total liabilities | $33.5M | $26.1M | $16.8M | — |
| Retained earnings | -$201.6M | -$138.4M | -$77.0M | — |
| Total equity | $151.1M | $151.5M | -$71.7M | -$38.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | -$51.8M | -$47.4M | -$33.4M | — |
| Depreciation and amortisation | $661.0K | $502.0K | $373.0K | — |
| Stock-based compensation | $8.1M | $7.6M | $2.9M | — |
| Capital expenditure | $24.0K | $2.1M | $470.0K | — |
| Investing cash flow | -$24.0K | -$2.1M | -$470.0K | — |
| Financing cash flow | $60.1M | $135.7M | $68.1M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001999480-26-000002.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Net income | — | -$36.3M | -$61.4M | -$63.2M |
Recent filings and events
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |